Zachary Bessette

Zachary Bessette

Articles by Zachary Bessette

Zachary BessetteLocalized | May 6, 2024
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Read More
Zachary BessetteTesticular, Penile, and Rare Malignancies | May 6, 2024
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Zachary BessetteUpper Tract Urothelial Carcinoma | May 21, 2024
For patients with clinical node-positive UTUC, NAC may lead to improved outcomes compared with adjuvant chemotherapy.
Zachary BessetteAdvanced Renal Cell Carcinoma | May 4, 2024
ICIs improves OS for patients with mRCC and sarcomatoid features who undergo CN, regardless of the timing of surgery.
Zachary BessetteMuscle Invasive Urothelial Carcinoma | May 3, 2024
RT to recurrence sites may not have an effect on oncologic outcomes in patients with MIBC after RC.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | May 3, 2024
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
Zachary BessetteMuscle Invasive Urothelial Carcinoma | May 3, 2024
Identifying tumor biomarkers associated with pCR to neoadjuvant pembro or NAC prior to cystectomy in patients with MIBC.
Zachary BessetteCRPC | May 3, 2024
Results from the third interim analysis of the DAROL study indicate real-world effectiveness in patients with nmCRPC.
Zachary BessetteRLT | April 30, 2024
A CR was observed in the first patient with mCRPC to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 23, 2024
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 16, 2024
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 15, 2024
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
Zachary BessetteLocalized Renal Cell Carcinoma | April 8, 2024
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 8, 2024
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Zachary BessetteLocalized | April 9, 2024
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
Zachary BessetteUpper Tract Urothelial Carcinoma | April 8, 2024
Patients who undergo RNU have comparative or better long-term outcomes than patients undergoing NSS for organ-localized UTUC.
Zachary BessetteAdvanced Urothelial Carcinoma | May 20, 2024
Approval came as a result of the CheckMate 901 study, a randomized trial that enrolled 608 patients with metastatic UC.
Zachary BessetteProstate Cancer Diagnostics | March 6, 2024
Clarity released updated data on COBRA, confirming that 64Cu-SAR-bisPSMA leads to higher detection of lesions in BCR.
Zachary BessettenccRCC | March 11, 2024
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Zachary BessetteProstate Cancer Diagnostics | February 15, 2024
Initial data from the COBRA trial confirm that 64Cu-SAR-bisPSMA is safe and “highly” effective in detecting BCR PC.